17.02.2010 • News

BASF Standardizes on Matrikon Control Performance Suite Globally

Matrikon Deutschland has entered a license agreement with BASF for all the company's production facilities worldwide to integrate and use Matrikon's Control Performance software suite with a variety of different control systems, thus establishing a DCS-independent, corporate standard for the evaluation and improvement of control performance. Matrikon will also support the solution rollout to BASF's major integrated European production sites in Ludwigshafen and Antwerp over the next 12 months.

Timo Klingenmeier, general manager of Matrikon Deutschland stated: "The bundled solution, with Matrikon Control Performance Monitor as a central component, will enable BASF to provide a standardized, control-focused key performance indicator system. The solution will support BASF's optimization efforts and assist with sustaining control performance improvements over the long term. We are very proud to be selected by BASF, being the global leader in chemical production."

Marcus Nohr, senior engineer and project lead for Automation Technology in BASF' Competence Center Engineering & Maintenance, said, "BASF conducted a rigorous evaluation of available control performance monitoring technologies and selected Matrikon as the currently most valuable solution for BASF. The combined rollout in Ludwigshafen and Antwerp is the base for control optimization worldwide. "

Company

Matrikon Deutschland AG

Venloer Str. 25
50672 Cologne
Germany

Company contact







Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read